Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.
IPO Year: 2021
Exchange: NASDAQ
Website: apria.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $37.50 | Buy → Neutral | UBS |
| 1/10/2022 | $39.00 | Buy | Citigroup |
| 11/19/2021 | $39.00 | Buy | Citigroup |
| 11/8/2021 | $43.00 | Buy | Citigroup |
| 7/19/2021 | $32.00 → $29.00 | Buy → Neutral | Goldman Sachs |
| 6/30/2021 | $33.00 | Buy | Citigroup |
Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil
INDIANAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal third quarter 2021 financial results on Thursday, November 4, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID 4161279; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listeni
INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5380517; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listen
INDIANAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of Christopher G. Lee as Chief Accounting Officer, a newly created position. Mr. Lee will report to Debra Morris, Apria's Chief Financial Officer. Mr. Lee has 18 years of accounting and financial leadership experience. He joined Apria in February 2009 and has risen internally to his most recent role as Senior Vice President, Accounting and Finance. Prior to joining Apria, Mr. Lee was with Deloitte & Touche. Mr. Lee is a graduate of the University of California a
UBS downgraded Apria from Buy to Neutral and set a new price target of $37.50
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $43.00
Goldman Sachs downgraded Apria from Buy to Neutral and set a new price target of $29.00 from $32.00 previously
Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $33.00
Citigroup initiated coverage of Apria with a rating of Buy and set a new price target of $33.00
The Goldman Sachs Group initiated coverage of Apria with a rating of Buy and set a new price target of $30.00
SC 13G/A - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G/A - Apria, Inc. (0001735803) (Subject)
SC 13G/A - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
SC 13G - Apria, Inc. (0001735803) (Subject)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
4 - Apria, Inc. (0001735803) (Issuer)
15-12B - Apria, Inc. (0001735803) (Filer)
25-NSE - Apria, Inc. (0001735803) (Subject)
S-8 POS - Apria, Inc. (0001735803) (Filer)
8-K - Apria, Inc. (0001735803) (Filer)
10-K/A - Apria, Inc. (0001735803) (Filer)
8-K - Apria, Inc. (0001735803) (Filer)
DEFA14A - Apria, Inc. (0001735803) (Filer)
8-K - Apria, Inc. (0001735803) (Filer)
10-K - Apria, Inc. (0001735803) (Filer)
8-K - Apria, Inc. (0001735803) (Filer)
INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. "We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth
INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States,
Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil
INDIANAPOLIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today the completion of a secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share, resulting in gross proceeds of $141.75 million. The selling stockholder has also granted the underwriters an option, exercisable for 30 days from November 10, 2021, to purchase up to an additional 675,000 shares of Class A common stock. Apria did not offer any shares of its common stock and did not receive any net proceeds from the sale of common stock by the selling stockholder. Citigroup and Goldm
INDIANAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today the pricing of a previously announced secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock. The offering is expected to close on November 15, 2021, subject to customary closing conditions. Apria is not offering any shares of its common stock and will not receive any net proceeds from the sale of common stock by the selling stockholder. Cit
INDIANAPOLIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that a selling stockholder affiliated with Blackstone has commenced a secondary offering of 4,500,000 shares of Apria common stock. In connection with the offering, the selling stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. Apria is not offering any shares of its common stock and will not receive any net proceeds from the sale of common stock by the selling stockholder. Citigroup and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. Citizens Capital Markets
INDIANAPOLIS, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the third quarter ended September 30, 2021. "We delivered solid third quarter 2021 financial results that were reflective of our continued execution and operational improvements building on momentum from the first half of the year, despite external headwinds. Third quarter revenue was in-line with our guidance while Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex were at the high end or better than our forecast," said Dan Starck, CEO o
INDIANAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal third quarter 2021 financial results on Thursday, November 4, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID 4161279; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listeni
INDIANAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of Christopher G. Lee as Chief Accounting Officer, a newly created position. Mr. Lee will report to Debra Morris, Apria's Chief Financial Officer. Mr. Lee has 18 years of accounting and financial leadership experience. He joined Apria in February 2009 and has risen internally to his most recent role as Senior Vice President, Accounting and Finance. Prior to joining Apria, Mr. Lee was with Deloitte & Touche. Mr. Lee is a graduate of the University of California a
INDIANAPOLIS, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the second quarter ended June 30, 2021. "We delivered another strong quarter as our second quarter 2021 financial results were ahead of our expectations on all three of our key metrics, achieving organic net revenue growth of over 6.0% as compared to the prior year quarter," said Dan Starck, CEO of Apria. "On July 30, we signed a definitive agreement to acquire Airway Breathing Co., a provider of respiratory care services, sleep equipment and supplies,
Although oil futures traded higher on Wednesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Inspire Medical Systems The Trade: Inspire Medical Systems, Inc. (NYSE:INSP) CEO and President Timothy P Herbert sold a total o
Merger activity remained steady with five new deals announced, four deals completed and one deal terminated. Two of the five new deals announced were potential deals in the works. TEGNA Inc. (NYSE:TGNA) Founded in 1906 and headquartered in Tysons, Virginia, TEGNA is a digital media and marketing services company. It was created on June 29, 2015, when the Gannett Company split into two publicly traded companies. We first added TEGNA as a potential deal in the works on August 16, 2019, when Apollo Global Management (NYSE:APO) approached the company about a deal. TEGNA’s price after this announcement was $14.28. On January 21, 2020, another large investor in Tegna (NYSE:TGNA) wanted the c
Apria (NASDAQ:APR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Apria missed estimated earnings by 2.22%, reporting an EPS of $0.44 versus an estimate of $0.45. Revenue was up $2.74 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.13 which was followed by a 2.35% drop in the share price the next day. Here's a look at Apria's past performance: Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate 0.47 0.38 0.25 0.23 EPS Actual 0.60 0.54 0.08 26.06 Re
Apria (NASDAQ:APR) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.45 by 2.22 percent. This is a 98.31 percent decrease over earnings of $26.06 per share from the same period last year. The company reported quarterly sales of $296.52 million which beat the analyst consensus estimate of $293.00 million by 1.20 percent. This is a 0.93 percent increase over sales of $293.79 million the same period last year.
Owens & Minor Inc (NYSE:OMI) has reported adjusted EPS of $0.81 in Q4, lower than $1.14 a year ago but ahead of the consensus of $0.71. Revenue for the quarter increased 4.45% to $2.47 billion, better than the consensus estimate of $2.43 billion. Global Solutions segment revenue grew 3% to $2 billion due to strong performance in Patient Direct business combined with increased PPE sales, partially offset by continued supplier shortages. Global Products segment revenue grew 9% to $629 million due to glove cost pass-through growth of non-PPE products. The acquisition of Apria Inc (NASDAQ:APR) remains on track to close in 1H of 2022. Excluding synergies, OMI expects Apria to generate:
Upgrades According to Bernstein, the prior rating for Dell Technologies Inc (NYSE:DELL) was changed from Market Perform to Outperform. Dell Technologies earned $2.37 in the third quarter, compared to $2.03 in the year-ago quarter. The stock has a 52-week-high of $115.00 and a 52-week-low of $53.01. At the end of the last trading period, Dell Technologies closed at $59.88. Barclays upgraded the previous rating for Illumina Inc (NASDAQ:ILMN) from Underweight to Equal-Weight. In the third quarter, Illumina showed an EPS of $1.45, compared to $1.02 from the year-ago quarter. The current stock performance of Illumina shows a 52-week-high of $555.77 and a 52-week-low of $341.03. Moreover, a
UBS analyst Whit Mayo downgrades Apria (NASDAQ:APR) from Buy to Neutral and announces $37.5 price target.
Gainers Bone Biologics Corporation (NASDAQ:BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ:ZNGA) rose 40.7% to settle at $8.44 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion. Molecular Partners AG (NASDAQ:MOLN) surged 30.5% to settle at $21.50 after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19. Reliance Global Group, Inc. (NASDAQ:RELI) climbed 28.9% to close at $7.86. Reliance Global Group, last month, announc
Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 61,263,030 cases with around 859,350 deaths. India confirmed a total of at least 35,708,440 cases and 483,930 deaths, while Brazil reported over 22,523,900 COVID-19 cases with 620,030 deaths. In total, there were at least 308,004,270 cases of COVID-19 worldwide with more than 5,507,340 deaths. Leading and Lagging Sectors Utilities shares fell by just 0.3% on Monday. Meanwhile, top gainers in the sector included Xcel Energy Inc. (N
Gainers Bone Biologics Corporation (NASDAQ:BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ:ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion. Apria, Inc. (NASDAQ:APR) shares climbed 25.1% to $37.17. Owens & Minor agreed to acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. Pluristem Therapeutics Inc. (NASDAQ:PSTI) gained 22.5% to $1.80. Pluristem Therapeutics and Tnuva Group have collaborated to develop, manufacture a